Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.

Lu X, Chen H, Patterson AV, Smaill JB, Ding K.

J Med Chem. 2018 Nov 16. doi: 10.1021/acs.jmedchem.8b01531. [Epub ahead of print]

PMID:
30403487
2.

Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.

Chan-Hyams JVE, Copp JN, Smaill JB, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2018 Dec;158:192-200. doi: 10.1016/j.bcp.2018.10.020. Epub 2018 Oct 21.

PMID:
30352235
3.

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.

Xiang Q, Wang C, Zhang Y, Xue X, Song M, Zhang C, Li C, Wu C, Li K, Hui X, Zhou Y, Smaill JB, Patterson AV, Wu D, Ding K, Xu Y.

Eur J Med Chem. 2018 Mar 10;147:238-252. doi: 10.1016/j.ejmech.2018.01.087. Epub 2018 Feb 6.

PMID:
29448139
4.

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

Mo C, Zhang Z, Guise CP, Li X, Luo J, Tu Z, Xu Y, Patterson AV, Smaill JB, Ren X, Lu X, Ding K.

ACS Med Chem Lett. 2017 Mar 31;8(5):543-548. doi: 10.1021/acsmedchemlett.7b00091. eCollection 2017 May 11.

5.

2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.

Li X, Guise CP, Taghipouran R, Yosaatmadja Y, Ashoorzadeh A, Paik WK, Squire CJ, Jiang S, Luo J, Xu Y, Tu ZC, Lu X, Ren X, Patterson AV, Smaill JB, Ding K.

Eur J Med Chem. 2017 Jul 28;135:531-543. doi: 10.1016/j.ejmech.2017.04.049. Epub 2017 Apr 22.

PMID:
28521156
6.

Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.

Copp JN, Mowday AM, Williams EM, Guise CP, Ashoorzadeh A, Sharrock AV, Flanagan JU, Smaill JB, Patterson AV, Ackerley DF.

Cell Chem Biol. 2017 Mar 16;24(3):391-403. doi: 10.1016/j.chembiol.2017.02.005. Epub 2017 Mar 2.

7.

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.

Mowday AM, Ashoorzadeh A, Williams EM, Copp JN, Silva S, Bull MR, Abbattista MR, Anderson RF, Flanagan JU, Guise CP, Ackerley DF, Smaill JB, Patterson AV.

Biochem Pharmacol. 2016 Sep 15;116:176-87. doi: 10.1016/j.bcp.2016.07.015. Epub 2016 Jul 22.

PMID:
27453434
8.

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress.

Mowday AM, Guise CP, Ackerley DF, Minton NP, Lambin P, Dubois LJ, Theys J, Smaill JB, Patterson AV.

Cancers (Basel). 2016 Jun 28;8(7). pii: E63. doi: 10.3390/cancers8070063. Review.

9.

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

Yosaatmadja Y, Silva S, Dickson JM, Patterson AV, Smaill JB, Flanagan JU, McKeage MJ, Squire CJ.

J Struct Biol. 2015 Dec;192(3):539-544. doi: 10.1016/j.jsb.2015.10.018. Epub 2015 Nov 2.

PMID:
26522274
10.

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.

Williams EM, Little RF, Mowday AM, Rich MH, Chan-Hyams JV, Copp JN, Smaill JB, Patterson AV, Ackerley DF.

Biochem J. 2015 Oct 15;471(2):131-53. doi: 10.1042/BJ20150650. Review.

PMID:
26431849
11.

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Abbattista MR, Jamieson SM, Gu Y, Nickel JE, Pullen SM, Patterson AV, Wilson WR, Guise CP.

Cancer Biol Ther. 2015;16(4):610-22. doi: 10.1080/15384047.2015.1017171. Epub 2015 Apr 14.

12.

The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition.

Yosaatmadja Y, Patterson AV, Smaill JB, Squire CJ.

Acta Crystallogr D Biol Crystallogr. 2015 Mar;71(Pt 3):525-33. doi: 10.1107/S1399004714027539. Epub 2015 Feb 26.

PMID:
25760602
13.

Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.

Wang J, Guise CP, Dachs GU, Phung Y, Hsu AH, Lambie NK, Patterson AV, Wilson WR.

Biochem Pharmacol. 2014 Oct 15;91(4):436-46. doi: 10.1016/j.bcp.2014.08.003. Epub 2014 Aug 15.

PMID:
25130546
14.

Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs.

Copp JN, Williams EM, Rich MH, Patterson AV, Smaill JB, Ackerley DF.

Protein Eng Des Sel. 2014 Oct;27(10):399-403. doi: 10.1093/protein/gzu025. Epub 2014 Jul 4.

PMID:
24996412
15.

Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.

Anderson RF, Yadav P, Patel D, Reynisson J, Tipparaju SR, Guise CP, Patterson AV, Denny WA, Maroz A, Shinde SS, Hay MP.

Org Biomol Chem. 2014 Jun 7;12(21):3386-92. doi: 10.1039/c4ob00236a. Epub 2014 Apr 16.

PMID:
24737463
16.

Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions.

Heapy AM, Patterson AV, Smaill JB, Jamieson SM, Guise CP, Sperry J, Hume PA, Rathwell K, Brimble MA.

Bioorg Med Chem. 2013 Dec 15;21(24):7971-80.

PMID:
24436995
17.

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.

Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, Mackenzie KL, Guise CP, Foehrenbacher A, Pullen SM, Benito J, Smaill JB, Patterson AV, Mulaw MA, Konopleva M, Bohlander SK, Lock RB, Wilson WR.

Biochem Pharmacol. 2014 Mar 1;88(1):36-45. doi: 10.1016/j.bcp.2013.12.019. Epub 2014 Jan 13.

PMID:
24434189
18.

The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.

Green LK, Storey MA, Williams EM, Patterson AV, Smaill JB, Copp JN, Ackerley DF.

Cancers (Basel). 2013 Aug 8;5(3):985-97. doi: 10.3390/cancers5030985.

19.

Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.

Su J, Gu Y, Pruijn FB, Smaill JB, Patterson AV, Guise CP, Wilson WR.

J Biol Chem. 2013 Dec 27;288(52):37138-53. doi: 10.1074/jbc.M113.505222. Epub 2013 Nov 6.

20.

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

Guise CP, Mowday AM, Ashoorzadeh A, Yuan R, Lin WH, Wu DH, Smaill JB, Patterson AV, Ding K.

Chin J Cancer. 2014 Feb;33(2):80-6. doi: 10.5732/cjc.012.10285. Epub 2013 Jul 12. Review.

21.

Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.

Green LK, Syddall SP, Carlin KM, Bell GD, Guise CP, Mowday AM, Hay MP, Smaill JB, Patterson AV, Ackerley DF.

Mol Cancer. 2013 Jun 10;12:58. doi: 10.1186/1476-4598-12-58.

22.

Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

Prosser GA, Copp JN, Mowday AM, Guise CP, Syddall SP, Williams EM, Horvat CN, Swe PM, Ashoorzadeh A, Denny WA, Smaill JB, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2013 Apr 15;85(8):1091-103. doi: 10.1016/j.bcp.2013.01.029. Epub 2013 Feb 8.

PMID:
23399641
23.

Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954.

Swe PM, Copp JN, Green LK, Guise CP, Mowday AM, Smaill JB, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2012 Sep 15;84(6):775-83. doi: 10.1016/j.bcp.2012.07.002. Epub 2012 Jul 14.

PMID:
22796568
24.

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.

Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS.

J Gene Med. 2012 Jul;14(7):445-58. doi: 10.1002/jgm.2630.

PMID:
22576955
25.

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP.

Mol Cancer Ther. 2012 Mar;11(3):740-51. doi: 10.1158/1535-7163.MCT-11-0634. Epub 2011 Dec 6.

26.

Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.

Hunt MA, Li D, Hay MP, Currie MJ, Robinson BA, Patterson AV, Dachs GU.

J Gene Med. 2012 Jan;14(1):62-74. doi: 10.1002/jgm.1635.

PMID:
22147660
27.

Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.

Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su J, Li D, Wilson WR, Dachs GU, Patterson AV.

Mol Pharmacol. 2012 Jan;81(1):31-40. doi: 10.1124/mol.111.073759. Epub 2011 Oct 7.

28.

uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954.

Prosser GA, Patterson AV, Ackerley DF.

J Biotechnol. 2010 Oct 1;150(1):190-4. doi: 10.1016/j.jbiotec.2010.08.007. Epub 2010 Aug 19.

PMID:
20727918
29.

Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.

Gu Y, Guise CP, Patel K, Abbattista MR, Li J, Sun X, Atwell GJ, Boyd M, Patterson AV, Wilson WR.

Cancer Chemother Pharmacol. 2011 Mar;67(3):543-55. doi: 10.1007/s00280-010-1354-5. Epub 2010 May 15. Erratum in: Cancer Chemother Pharmacol. 2011 May;67(5):1209. Lie, Jie [corrected to Li, Jie].

PMID:
20473609
30.

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV.

Cancer Res. 2010 Feb 15;70(4):1573-84. doi: 10.1158/0008-5472.CAN-09-3237. Epub 2010 Feb 9.

31.

Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Shinde SS, Maroz A, Hay MP, Patterson AV, Denny WA, Anderson RF.

J Am Chem Soc. 2010 Mar 3;132(8):2591-9. doi: 10.1021/ja908689f.

PMID:
20141134
32.

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR.

Cancer Chemother Pharmacol. 2010 Mar;65(4):791-801. doi: 10.1007/s00280-009-1188-1. Epub 2009 Dec 10.

PMID:
20012293
33.

Bystander or no bystander for gene directed enzyme prodrug therapy.

Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV.

Molecules. 2009 Nov 10;14(11):4517-45. doi: 10.3390/molecules14114517. Review.

34.

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2010 Mar 1;79(5):678-87. doi: 10.1016/j.bcp.2009.10.008. Epub 2009 Oct 21.

PMID:
19852945
35.

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.

Wilson WR, Stribbling SM, Pruijn FB, Syddall SP, Patterson AV, Liyanage HD, Smith E, Botting KJ, Tercel M.

Mol Cancer Ther. 2009 Oct;8(10):2903-13. doi: 10.1158/1535-7163.MCT-09-0571. Epub 2009 Oct 6.

36.

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.

Shinde SS, Hay MP, Patterson AV, Denny WA, Anderson RF.

J Am Chem Soc. 2009 Oct 14;131(40):14220-1. doi: 10.1021/ja906860a.

PMID:
19772319
37.

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.

Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, Wilson WR.

Mol Cancer Ther. 2009 Jun;8(6):1714-23. doi: 10.1158/1535-7163.MCT-08-1209. Epub 2009 Jun 9.

38.

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR.

Cancer Res. 2009 May 1;69(9):3884-91. doi: 10.1158/0008-5472.CAN-08-4023. Epub 2009 Apr 14.

39.

Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV, Brown JM.

Cancer Res. 2008 Oct 1;68(19):7995-8003. doi: 10.1158/0008-5472.CAN-08-1698.

40.

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).

Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV.

Cancer Gene Ther. 2007 Dec;14(12):953-67. Epub 2007 Nov 2.

PMID:
17975564
41.

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.

Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):560-71.

PMID:
17869669
42.

Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.

Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV.

Biochem Pharmacol. 2007 Sep 15;74(6):810-20. Epub 2007 Jun 17.

PMID:
17645874
43.

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR.

Clin Cancer Res. 2007 Jul 1;13(13):3922-32.

44.

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.

Radiat Res. 2007 Jun;167(6):625-36.

PMID:
17523848
45.

Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.

Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, Wilson WR, Denny WA.

J Med Chem. 2007 Mar 22;50(6):1197-212. Epub 2007 Feb 28.

PMID:
17326614
46.

Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.

Ahn GO, Botting KJ, Patterson AV, Ware DC, Tercel M, Wilson WR.

Biochem Pharmacol. 2006 Jun 14;71(12):1683-94. Epub 2006 Mar 14.

PMID:
16620789
47.

Cancer chemotherapy and drug metabolism.

Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ, Patterson AV, Stratford IJ, Morrow CS, Townsend AJ, Jounaidi Y, Chen CS, Su T, Lu H, Schwartz PS, Waxman DJ.

Drug Metab Dispos. 2005 Aug;33(8):1083-96.

48.

Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells.

Chadderton N, Cowen RL, Sheppard FC, Robinson S, Greco O, Scott SD, Stratford IJ, Patterson AV, Williams KJ.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):213-22.

PMID:
15850924
49.

Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs.

Phillips RM, Jaffar M, Maitland DJ, Loadman PM, Shnyder SD, Steans G, Cooper PA, Race A, Patterson AV, Stratford IJ.

Biochem Pharmacol. 2004 Dec 1;68(11):2107-16.

PMID:
15498501
50.

The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.

Kim JY, Patterson AV, Stratford IJ, Hendry JH.

Anticancer Drugs. 2004 Jan;15(1):71-7.

PMID:
15090746

Supplemental Content

Loading ...
Support Center